AfaSci

Executive Summary

AfaSci Inc. is a privately held biopharmaceutical company based in Redwood City, California, founded in 2008. The company focuses on developing novel small molecule therapeutics for central nervous system (CNS) disorders, including chronic pain and epilepsy. Its lead candidate, AFA-281, is an orally available small molecule designed to address these indications. In addition to drug development, AfaSci operates subsidiaries that provide preclinical contract research services and commercialize automated rodent behavioral monitoring instruments, creating multiple revenue streams. While the company has not disclosed significant funding or valuation details, its integrated business model and focus on CNS conditions with high unmet need position it for potential growth. Key upcoming catalysts include advancement of AFA-281 into later-stage clinical trials, which could provide proof-of-concept data and attract partnership interest.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 2 trial for AFA-281 in chronic pain40% success
• Q3 2026Preclinical data readout for AFA-281 in epilepsy models60% success
• 2027Potential partnership or licensing deal for CNS pipeline30% success